Literature DB >> 28490785

The rise of IL-2 therapy - a picture beyond Treg cells.

Zhanguo Li1, Jing He1, Di Yu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28490785     DOI： 10.1038/nrrheum.2017.70

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  12 in total

1.  Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.

Authors:  Jing He; Louis M Tsai; Yew Ann Leong; Xin Hu; Cindy S Ma; Nina Chevalier; Xiaolin Sun; Kirsten Vandenberg; Steve Rockman; Yan Ding; Lei Zhu; Wei Wei; Changqi Wang; Alexander Karnowski; Gabrielle T Belz; Joanna R Ghali; Matthew C Cook; D Sean Riminton; André Veillette; Pamela L Schwartzberg; Fabienne Mackay; Robert Brink; Stuart G Tangye; Carola G Vinuesa; Charles R Mackay; Zhanguo Li; Di Yu
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

2.  Clinical trials: The rise of IL-2 therapy - a novel biologic treatment for SLE.

Authors:  Jens Y Humrich; Gabriela Riemekasten
Journal:  Nat Rev Rheumatol       Date:  2016-10-20       Impact factor: 20.543

3.  Interleukin-2 and regulatory T cells in graft-versus-host disease.

Authors:  John Koreth; Ken-ichi Matsuoka; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Edwin P Alyea; Philippe Armand; Corey Cutler; Vincent T Ho; Nathaniel S Treister; Don C Bienfang; Sashank Prasad; Dmitrios Tzachanis; Robin M Joyce; David E Avigan; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

4.  Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.

Authors:  André Ballesteros-Tato; Beatriz León; Beth A Graf; Amy Moquin; Pamela Scott Adams; Frances E Lund; Troy D Randall
Journal:  Immunity       Date:  2012-03-29       Impact factor: 31.745

5.  Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.

Authors:  Caroline von Spee-Mayer; Elise Siegert; Dimas Abdirama; Angelika Rose; Anika Klaus; Tobias Alexander; Philipp Enghard; Birgit Sawitzki; Falk Hiepe; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten; Jens Y Humrich
Journal:  Ann Rheum Dis       Date:  2015-08-31       Impact factor: 19.103

6.  Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.

Authors:  Jing He; Xia Zhang; Yunbo Wei; Xiaolin Sun; Yaping Chen; Jun Deng; Yuebo Jin; Yuzhou Gan; Xin Hu; Rulin Jia; Chuanhui Xu; Zhaohua Hou; Yew Ann Leong; Lei Zhu; Jinhong Feng; Yuan An; Yuan Jia; Chun Li; Xu Liu; Hua Ye; Limin Ren; Ru Li; Haihong Yao; Yuhui Li; Shi Chen; Xuewu Zhang; Yin Su; Jianping Guo; Nan Shen; Eric F Morand; Di Yu; Zhanguo Li
Journal:  Nat Med       Date:  2016-08-08       Impact factor: 53.440

7.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

Authors:  Arian Laurence; Cristina M Tato; Todd S Davidson; Yuka Kanno; Zhi Chen; Zhengju Yao; Rebecca B Blank; Françoise Meylan; Richard Siegel; Lothar Hennighausen; Ethan M Shevach; John J O'shea
Journal:  Immunity       Date:  2007-03       Impact factor: 31.745

8.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

Authors:  Makoto Miyara; Yumiko Yoshioka; Akihiko Kitoh; Tomoko Shima; Kajsa Wing; Akira Niwa; Christophe Parizot; Cécile Taflin; Toshio Heike; Dominique Valeyre; Alexis Mathian; Tatsutoshi Nakahata; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono; Zahir Amoura; Guy Gorochov; Shimon Sakaguchi
Journal:  Immunity       Date:  2009-05-21       Impact factor: 31.745

9.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.

Authors:  Nabila Seddiki; Brigitte Santner-Nanan; Jeff Martinson; John Zaunders; Sarah Sasson; Alan Landay; Michael Solomon; Warwick Selby; Stephen I Alexander; Ralph Nanan; Anthony Kelleher; Barbara Fazekas de St Groth
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307
View more
  2 in total

1.  Low-dose IL-2 therapy - a complex scenario that remains to be further explored.

Authors:  Jens Y Humrich; Gabriela Riemekasten
Journal:  Nat Rev Rheumatol       Date:  2017-05-11       Impact factor: 20.543

2.  Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2.

Authors:  Dan Long; Shujiao Yu; Lu Zhang; Yang Guo; Shumin Xu; Yuting Rao; Zikun Huang; Qing Luo; Junming Li
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.